Effect of pathohistologic complete remission (pCR) rate on the prediction of long-term prognosis following chemoradiotherapy (XRT) with cetuximab (Cet), capecitabine (CAP), and oxaliplatin (OX; Cet-CAPOX) in patients (pts) with locally advanced rectal cancer (LARC).
T. Liersch
No relevant relationships to disclose
C. Weiss
No relevant relationships to disclose
K. Dellas
No relevant relationships to disclose
M. Hipp
No relevant relationships to disclose
R. Sauer
No relevant relationships to disclose
C. Rödel
Honoraria - Merck KGaA; Roche; Sanofi
Research Funding - Merck KGaA; Roche; Sanofi
D. Arnold
Honoraria - Merck KGaA; Roche; Sanofi
Research Funding - Merck KGaA; Roche; Sanofi